Contemporary evaluation of acute myeloid leukemia patients with long‐term survival exceeding 5 years

Objectives Define clinical and laboratory attributes of acute myeloid leukemia (AML) patients with long‐term survival exceeding five years and compare them with AML patients succumbing to disease within 2 years of diagnosis. Methods A retrospective analysis of AML patients alive at least five years from the time of initial diagnosis. Baseline clinical data were compared with patients who died within 2 years of diagnosis. Results The long‐term cohort consisted of 93 patients treated in 2007–2016 with a median follow‐up duration of 7.7 years (range 5–13.6 years). European LeukemiaNet (ELN) 2017 favorable risk patients accounted for 60% of the cohort. All long‐term survivors achieved remission following induction chemotherapy. Multivariate analysis showed that compared with 132 patients experiencing death within 2 years of diagnosis, long‐term survivors were more likely to be of younger age [odds ratio (OR), 0.92; 95% confidence interval (CI), 0.9–0.95; p